Table 22 (abstract P270). Comparison of disease activity and damage between the “methotrexate” and “biologic” eras
From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two
“Methotrexate” era£ (n = 310) N. (%) | “Biologic” era (n =152) N. (%) | |
|---|---|---|
Patients with no active joints | 92 (29.8) | 96 (63.2) |
Patients with no restricted joints | 126 (40.8) | 101 (66.5) |
Patients with physician global assessment = 0 | 89 (29.6) | 94 (61.8) |
Patients with inactive disease on JADAS10 | 64 (20.6) | 40 (26.3) |
Patients with inactive disease on cJADAS10 | 73 (23.5) | 62 (40.8) |
Functional ability score = 0 | 155 (51.3) $ | 83 (54.6) § |
Patients with JADI-articular = 0 | 204 (65.8) | 124 (81.6) |
Patients with JADI-extraarticular = 0 | 229 (73.9) | 128 (84.2) |